NYSEARCA:SCPX - NYSE Arca - US42237K5083 - Common Stock - Currency: USD
NYSEARCA:SCPX (4/21/2025, 8:04:00 PM)
0.068
-0.06 (-48.48%)
The current stock price of SCPX is 0.068 USD. In the past month the price decreased by -59.04%. In the past year, price decreased by -78.97%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.82 | 319.07B | ||
AMGN | AMGEN INC | 14.12 | 150.46B | ||
GILD | GILEAD SCIENCES INC | 13.71 | 132.33B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1698.17 | 126.60B | ||
REGN | REGENERON PHARMACEUTICALS | 13.14 | 65.57B | ||
ARGX | ARGENX SE - ADR | 322.85 | 36.67B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.56B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.98B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.60B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 27.06B | ||
NTRA | NATERA INC | N/A | 20.88B | ||
BIIB | BIOGEN INC | 7.26 | 17.49B |
Scorpius Holdings, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company is headquartered in San Antonio, Texas and currently employs 82 full-time employees. The company went IPO on 2013-07-24. The firm couples Current Good Manufacturing Practices (CGMP) biomanufacturing and quality control knowledge with capabilities in immunoassays, molecular assays, and bioanalytical methods to support cell- and gene-based therapies as well as large molecule biologics using American-made equipment, reagents, and materials. The company offers an array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its facilities in San Antonio, Texas. The firm's CDMO service offerings also include enhanced microbial and mammalian development and manufacturing services.
SCORPIUS HOLDINGS INC
1305 E. Houston Street, Building 2
San Antonio TEXAS US
Employees: 83
Company Website: https://www.nighthawkbio.com/
Investor Relations: https://www.nighthawkbio.com/investors-news
Phone: 19192407133
The current stock price of SCPX is 0.068 USD. The price decreased by -48.48% in the last trading session.
The exchange symbol of SCORPIUS HOLDINGS INC is SCPX and it is listed on the NYSE Arca exchange.
SCPX stock is listed on the NYSE Arca exchange.
7 analysts have analysed SCPX and the average price target is 5.1 USD. This implies a price increase of 7400% is expected in the next year compared to the current price of 0.068. Check the SCORPIUS HOLDINGS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
SCORPIUS HOLDINGS INC (SCPX) has a market capitalization of 331.16K USD. This makes SCPX a Nano Cap stock.
SCORPIUS HOLDINGS INC (SCPX) currently has 83 employees.
SCORPIUS HOLDINGS INC (SCPX) has a resistance level at 0.13. Check the full technical report for a detailed analysis of SCPX support and resistance levels.
The Revenue of SCORPIUS HOLDINGS INC (SCPX) is expected to grow by 63.27% in the next year. Check the estimates tab for more information on the SCPX EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
SCPX does not pay a dividend.
SCORPIUS HOLDINGS INC (SCPX) will report earnings on 2025-05-26.
SCORPIUS HOLDINGS INC (SCPX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.38).
The outstanding short interest for SCORPIUS HOLDINGS INC (SCPX) is 79.4% of its float. Check the ownership tab for more information on the SCPX short interest.
ChartMill assigns a fundamental rating of 2 / 10 to SCPX. SCPX may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months SCPX reported a non-GAAP Earnings per Share(EPS) of -1.38. The EPS increased by 20.42% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -72.96% | ||
ROE | -128.83% | ||
Debt/Equity | 0.31 |
ChartMill assigns a Buy % Consensus number of 83% to SCPX. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 97.7% and a revenue growth 63.27% for SCPX